SOTIO Completes Enrollment for Phase 3 Trial of DCVAC/PCa Immunotherapy

SOTIO Completes Enrollment for Phase 3 Trial of DCVAC/PCa Immunotherapy
The Phase 3 trial evaluating the immunotherapy DCVAC/PCa in men with metastatic castration-resistant prostate cancer (mCRPC), has completed patient enrollment, according to trial sponsor, SOTIO. The treatment is being evaluated as an add-on to standard of care chemotherapy – Taxotere (docetaxel) – for patients who have not received prior chemotherapy. “The completion of the patient enrolment

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *